The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?

Area of Science:

• Cardiology
• Public Health

Background:

• The DA VINCI study is an EU-wide observational study assessing lipid-lowering therapy (LLT) use.
• It evaluated achievement of European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) goals.

Purpose of the Study:

• This analysis focuses on Irish patients within the DA VINCI study.
• To evaluate LDL-C goal attainment in Irish primary and secondary care patients receiving LLT.

Main Methods:

• Subgroup analysis of the DA VINCI study cohort in Ireland.
• Included 198 patients from primary and secondary care sites.
• Assessed achievement of 2016 and 2019 ESC/EAS LDL-C goals.

Main Results:

• Most patients received moderate- to high-intensity statin therapy (atorvastatin or rosuvastatin).
• Approximately 60% achieved 2016 LDL-C goals; less than half achieved 2019 goals.
• Only 20% of secondary prevention patients achieved their 2019 ESC/EAS LDL-C goals.

Conclusions:

• Significant disparity exists between current dyslipidemia management in Ireland and guideline recommendations.
• Current LLT practices fall short of ESC/EAS targets, particularly for 2019 goals.
• Highlights the need for improved strategies to meet lipid targets in Irish patients.